Pubblicazioni

Autori:

Francica, Alessandra; Tonelli, Filippo; Saran, Alberto; Pesarini, Gabriele; Vendramin, Igor; Tabbì, Rocco; Rossetti, Cecilia; Luciani, Giovanni Battista; Ribichini, Flavio L; Onorati, Francesco

Titolo:

Transapical Transcatheter Aortic Valve Replacement: A Real-World Early and Mid-Term Outcome of a Third-Level Centre

Anno:

2022

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

JOURNAL OF CLINICAL MEDICINE

ISSN Rivista:

2077-0383

N° Volume:

11

Numero o Fascicolo:

14

Intervallo pagine:

4158-4169

Parole chiave:

Heart-Team; severe aortic valve stenosis; transapical transchateter aortic valve replacement; transapical valve-in-valve implantation; transchateter aortic valve implantation

Breve descrizione dei contenuti:

Background: Transapical transcatheter aortic valve replacement (TA-TAVR) is generally considered to be associated with higher morbidity compared with transfemoral-TAVR. However, TA-TAVR remains a feasible alternative for patients who are unsuitable for TF-TAVR. It has been shown that outcomes after TAVR are linked to the operator's expertise. Therefore, the purpose of this study is to report short- and mid-term outcomes after TA-TAVR performed by an expert Heart-Team of a third-level centre. Methods: From 2015 to 2022, 154 consecutive patients underwent TA-TAVR. The outcomes were analysed according to the VARC-3 criteria. Kaplan-Meier curves were estimated for major clinical events at mid-term follow-up. Results: The mean age of the population was 79.3 years and the STS risk-score of mortality was 4.2 ± 3.6%. Periprocedural mortality was 1.9%. Acute kidney injury and prolonged ventilation occurred in 1.9%. Incidence of stroke was 0.6%. Pacemaker implantation rate was 1.9%. Freedom from cardiovascular mortality was 75.7%, and 60.2% at 3 and 5 years. Freedom from stroke was 92.3% and 88.9% at 3 and 5 years, respectively; freedom from endocarditis was 94.4% and 90.8% at 3 and 5 years, respectively. Conclusion: TA-TAVR may be considered a safe and effective alternative approach in patients unsuitable for TF-TAVR, especially when performed by a proficient Heart-Team.

Id prodotto:

131203

Handle IRIS:

11562/1082908

ultima modifica:

23 febbraio 2023

Citazione bibliografica:

Francica, Alessandra; Tonelli, Filippo; Saran, Alberto; Pesarini, Gabriele; Vendramin, Igor; Tabbì, Rocco; Rossetti, Cecilia; Luciani, Giovanni Battista; Ribichini, Flavio L; Onorati, Francesco, Transapical Transcatheter Aortic Valve Replacement: A Real-World Early and Mid-Term Outcome of a Third-Level Centre «JOURNAL OF CLINICAL MEDICINE» , vol. 11 , n. 14 , 2022 , pp. 4158-4169

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo